Papers - TANAKA Hisashi
-
Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer.
Morinaga D, Hashimoto K, Asahina H, Tanaka H, Honjo O, Harada T, Yokouchi H, Kikuchi H, Shigaki R, Takashina T, Nakamura K, Kawai Y, Takahashi M, Kida R, Sukoh N, Ito K, Takahashi A, Hommura H, Ohhara Y, Furuta M, Konno S, Hosomi Y, Oizumi S.
Respir Investig. 17 ( 63 ) 373 - 382 2025.3
-
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Kinoshita F, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Yamaguchi M, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Yamamoto K, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
Ther Adv Med Oncol. 2025.3
-
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Kinoshita F, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Yamaguchi M, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Yamamoto K, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
Ther Adv Med Oncol. 2025.3
-
Tripartite motif 22 (TRIM22) downregulates TLR3-induced CCL5 expression in human renal proximal tubular epithelial cells.
Tachizaki M, Kobori Y, Kawaguchi S, Seya K, Tanaka H, Imaizumi T
Molecular biology reports 52 ( 1 ) 306 2025.3
-
Rapidly progressing nuclear protein in testis carcinoma of the lung in a young woman that was treated with chemotherapy plus immune checkpoint inhibitors: A case report
Oyama Shintaro, Tanaka Hisashi, Taima Kageaki, Makiguchi Tomonori, Sakamoto Hiroaki, Tasaka Sadatomo
Annals of the Japanese Respiratory Society 14 ( 2 ) 62 - 67 2025.3
-
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K.
Lung Cancer 2025.3
-
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K
Lung cancer (Amsterdam, Netherlands) 201 108447 2025.3
-
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Kinoshita F, Fujishita T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Ishikawa N, Kozuki T, Kawamura T, Saito G, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Nishii K, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
Ther Adv Med Oncol. 2025.2
-
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Kinoshita F, Fujishita T, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Hata A, Ishikawa N, Kozuki T, Kawamura T, Saito G, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Nishii K, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N.
Ther Adv Med Oncol. 2025.2
-
Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Yamana K, Kandori S, Kimura T, Nishiyama N, Bando Y, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Kitamura H, Miyake H, Habuchi T
Cancer science 116 ( 2 ) 444 - 452 2025.2
-
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
Fujimoto D, Shibaki R, Kimura K, Haratani K, Tamiya M, Kijima T, Sato Y, Hata A, Yokoyama T, Taniguchi Y, Uchida J, Tanaka H, Furuya N, Miura S, Onishi MI, Sakata S, Miyauchi E, Yamamoto N, Koh Y, Akamatsu H.
Lung Cancer. 2025.1
-
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H.
Lung Cancer. 2025.1
-
PD-L1 expression on tumor cells and tumor-infiltrating immune cells in thymic epithelial tumors detected with SP142 and SP263 antibodies.
Chubachi K, Tanaka H, Taima K, Tasaka S, Kurose A
PloS one 20 ( 7 ) e0327792 2025
-
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Kinoshita F, Tanzawa S, Misumi T, Yoshioka H, Miyauchi E, Ninomiya K, Murata Y, Takeshita M, Yamaguchi M, Sugawara S, Kawashima Y, Hashimoto K, Mori M, Miyanaga A, Hayashi A, Tanaka H, Honda R, Nojiri M, Sato Y, Yamamoto K, Masuda K, Kozuki T, Kawamura T, Suzuki T, Yamaguchi T, Asada K, Tetsumoto S, Tanaka H, Watanabe S, Umeda Y, Yamaguchi K, Kuyama S, Tsuruno K, Misumi Y, Kuraishi H, Yoshihara K, Nakao A, Kubo A, Yokoyama T, Watanabe K, Seki N
Therapeutic advances in medical oncology 17 17588359241312503 2025
-
Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study.
Makiguchi T, Tanaka H, Morikawa K, Hirata A, Itani H, Tanzawa S, Watanabe K, Yasuda H, Horiuchi K, Nakagawa H, Seki Y, Nakahara Y, Hayashi K, Takahashi N, Endo T, Bessho A, Okano T, Takeyama K, Kawase A, Endo M, Maekura T, Nemoto K, Takigawa N, Kishi K, Soejima K, Okuma Y, Togashi A, Matsutani N, Shinchi H, Ueda K, Seki N
Cancer treatment and research communications 44 100952 2025
-
A case of triple synchronous lung cancer in the same lobe associated with old pulmonary tuberculosis
Chiba Shunsuke, Taima Kageaki, Tanaka Hisashi, Makiguchi Tomonori, Nunomura Yasuhito, Tasaka Sadatomo
Annals of the Japanese Respiratory Society 14 ( 6 ) 386 - 389 2025
-
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.
Miura K, Shukuya T, Furuya N, Morita R, Kisohara A, Mouri A, Watanabe S, Tanaka H, Hirata A, Hakozaki T, Hamai K, Matsumoto N, Watanabe K, Ashinuma H, Miyauchi E, Sugano K, Hosokawa S, Amano K, Morita S, Kobayashi K, Maemonodo M, Takahashi K.
J Cachexia Sarcopenia Muscle. 2024.12
-
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M.
Eur J Cancer. 2024.12
-
Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
Tabe C, Fujita T, Taima K, Tanaka H, Makiguchi T, Itoga M, Ishioka Y, Tasaka S, Fujii H.
Lung Cancer. 197 2024.11
-
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T, Iwashima A, Sugisaka J, Miura Y, Tanaka H, Miyawaki T, Yokouchi H, Miura K, Saito R, Saito G, Kamoshida T, Uchinami Y, Kato T, Kobayashi K, Asahina H.
Cancer Sci. 2024.11